Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection

BackgroundThe prostate gland represents a multifaceted system in which prostate epithelia and stroma have distinct physiological roles. To understand the interaction between stroma and glandular epithelia, it is essential to delineate the gene expression profiles of these two tissue types in prostate cancer. Most studies have compared tumor and normal samples by performing global expression analysis using a mixture of cell populations. This report presents the first study of prostate tumor tissue that examines patterns of differential expression between specific cell types using laser capture microdissection (LCM).MethodsLCM was used to isolate distinct cell-type populations and identify their gene expression differences using oligonucleotide microarrays. Ten differentially expressed genes were then analyzed in paired tumor and non-neoplastic prostate tissues by quantitative real-time PCR. Expression patterns of the transcription factors, WT1 and EGR1, were further compared in established prostate cell lines. WT1 protein expression was also examined in prostate tissue microarrays using immunohistochemistry.ResultsThe two-step method of laser capture and microarray analysis identified nearly 500 genes whose expression levels were significantly different in prostate epithelial versus stromal tissues. Several genes expressed in epithelial cells (WT1, GATA2, and FGFR-3) were more highly expressed in neoplastic than in non-neoplastic tissues; conversely several genes expressed in stromal cells (CCL5, CXCL13, IGF-1, FGF-2, and IGFBP3) were more highly expressed in non-neoplastic than in neoplastic tissues. Notably, EGR1 was also differentially expressed between epithelial and stromal tissues. Expression of WT1 and EGR1 in cell lines was consistent with these patterns of differential expression. Importantly, WT1 protein expression was demonstrated in tumor tissues and was absent in normal and benign tissues.ConclusionsThe prostate represents a complex mix of cell types and there is a need to analyze distinct cell populations to better understand their potential interactions. In the present study, LCM and microarray analysis were used to identify novel gene expression patterns in prostate cell populations, including identification of WT1 expression in epithelial cells. The relevance of WT1 expression in prostate cancer was confirmed by analysis of tumor tissue and cell lines, suggesting a potential role for WT1 in prostate tumorigenesis.

[1]  D. Tindall,et al.  Expression of early growth response genes in human prostate cancer. , 1998, Cancer research.

[2]  Ruth Etzioni,et al.  IGF‐I and IGFBP‐3 polymorphisms and risk of prostate cancer , 2005, The Prostate.

[3]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[4]  H. Kantarjian,et al.  WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia , 1999, Leukemia.

[5]  D. Mercola,et al.  The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin , 2006, Cancer Gene Therapy.

[6]  T. Werner,et al.  Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens , 2008, Prostate Cancer and Prostatic Diseases.

[7]  H. Ackermann,et al.  The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia , 2002, Leukemia.

[8]  J. Droz,et al.  Insulin-Like Growth Factor (IGF) family and prostate cancer. , 2006, Critical reviews in oncology/hematology.

[9]  Helen Piontkivska,et al.  Evolutionary conservation of zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer , 2008, BMC Genomics.

[10]  P. Thall,et al.  Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. , 2009, Journal of the National Cancer Institute.

[11]  G. Fraizer,et al.  Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. , 2007, Frontiers in bioscience : a journal and virtual library.

[12]  S M Hewitt,et al.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.

[13]  W. Hahn,et al.  Prostate cancer: Re-focusing on androgen receptor signaling. , 2007, The international journal of biochemistry & cell biology.

[14]  E. Kjeldsen,et al.  WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study , 2004, British journal of haematology.

[15]  A. Gurney,et al.  Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. , 1996, The EMBO journal.

[16]  Pierre Baldi,et al.  Global Gene Expression Profiling in Escherichia coliK12 , 2002, The Journal of Biological Chemistry.

[17]  D. Housman,et al.  Alternative splicing and genomic structure of the Wilms tumor gene WT1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[19]  G. Mize,et al.  Prostate-Specific Kallikreins-2 and -4 Enhance the Proliferation of DU-145 Prostate Cancer Cells through Protease-Activated Receptors-1 and -2 , 2008, Molecular Cancer Research.

[20]  D. Peehl.  Primary cell cultures as models of prostate cancer development. , 2005, Endocrine-related cancer.

[21]  H. Piontkivska,et al.  Uncovering Androgen Responsive Regulatory Networks in Prostate Cancer , 2009, 2009 Ohio Collaborative Conference on Bioinformatics.

[22]  C. Roberts,et al.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Geater,et al.  WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study , 2006, BMC Cancer.

[25]  R. Hruban,et al.  SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions , 2003, Oncogene.

[26]  S. Mundlos,et al.  Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. , 1993, Development.

[27]  F. Habib,et al.  The insulin-like growth factor type I receptor stimulates growth and suppresses apoptosis in prostatic stromal cells. , 1998, The Journal of clinical endocrinology and metabolism.

[28]  Vladimir Makarov,et al.  Whole transcriptome amplification for gene expression profiling and development of molecular archives. , 2006, Neoplasia.

[29]  D. Goodlett,et al.  Stromal mesenchyme cell genes of the human prostate and bladder , 2005, BMC urology.

[30]  E. Devilard,et al.  FGFR1 and WT1 are markers of human prostate cancer progression , 2006, BMC Cancer.

[31]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[32]  M. Niksic,et al.  The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. , 2003, Human molecular genetics.

[33]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[35]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[36]  M. Grzmil,et al.  cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and non-neoplastic prostate tissue separated by laser microdissections. , 2004, International journal of oncology.

[37]  W. Lopaczynski,et al.  Preprostatectomy: A clinical model to study stromal-epithelial interactions. , 2001, Urology.

[38]  M. Ittmann,et al.  Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  M. Little,et al.  The Wilms’ tumour suppressor protein, WT1, undergoes CRM1‐independent nucleocytoplasmic shuttling , 2003, FEBS letters.

[40]  Matthias Kretzler,et al.  Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. , 2002, The American journal of pathology.

[41]  P. Nelson,et al.  Prostate Cancer–Associated Gene Expression Alterations Determined from Needle Biopsies , 2009, Clinical Cancer Research.

[42]  L. Chung,et al.  Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. , 2002, Differentiation; research in biological diversity.

[43]  E Helene Sage,et al.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. , 2003, Cancer research.

[44]  G. Saunders,et al.  The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  L. Chung,et al.  New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions. , 2003, Urology.

[46]  Rajiv Dhir,et al.  Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors , 2005, BMC Cancer.

[47]  L. Chung,et al.  Prostate epithelial differentiation is dictated by its surrounding stroma , 2004, Molecular Biology Reports.

[48]  Rajiv Dhir,et al.  Gene expression analysis of prostate cancers , 2002, Molecular carcinogenesis.

[49]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[50]  T. Hunter,et al.  Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain , 1997, Oncogene.

[51]  Mustafa Ozen,et al.  Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.

[52]  V. Sukhatme,et al.  Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. , 1994, The Journal of biological chemistry.

[53]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[54]  Y. Miyoshi,et al.  High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  J. Geradts,et al.  Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. , 2007, Human pathology.

[56]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[57]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[58]  D. Allred,et al.  Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. , 2009, Archives of pathology & laboratory medicine.

[59]  D. Peehl,et al.  Expression of CCL5 (RANTES) and CCR5 in prostate cancer , 2006, The Prostate.

[60]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[61]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[62]  Xiaochong Wu,et al.  Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. , 2003, Cancer research.